Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.

Objectives: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and CYP3A inhibitor fluconazole (Study A), and (2) with three different CYP2C9 genotype variants (Stu...

Descripción completa

Detalles Bibliográficos

Publicado en:	Clinical Pharmacokinetics Vol. 58; no. 3; pp. 349 - 362
Autores principales:	Gardin, Anne, Ufer, Mike, Legangneux, Eric, Rossato, Gianluca, Jin, Yi, Su, Zhenzhong, Pal, Parasar, Li, Wenkui, Shakeri-Nejad, Kasra
Formato:	research Journal Article
Publicado:	Springer Nature Mar2019
Acceso en línea:	Ver este registro en EBSCOhost